

Verification of Quantitativity and Confirmation of Molecular Weight of Oligonucleotide Therapeutics Using LCMS™-8060

■ Overview

Oligonucleotide therapeutics are synthetic oligonucleotides which demonstrate medical efficacy by bonding with target genes or target proteins that cause various diseases.

This article introduces an example of an analysis of a 20 base 2'-MOE modified oligonucleotide using an LCMS-8060 triple quadrupole mass spectrometer. In preparation of the calibration curve in the MRM mode, linearity was confirmed in the range of 1 to 300 ng/mL, and the molecular weight was confirmed by deconvolution from the multivalent ion mass spectrum obtained in the scan mode.

N. Kato

■ Analysis Conditions

Table 1 shows the HPLC and MS analysis conditions. An ion-pair reagent is generally used in reversed phase separation of oligonucleotides, and TEA*1 is often used as an amine-type reagent. Here, HFIP*2 and DIPEA*3 were used in the mobile phase, as these substances enable measurement with higher sensitivity.

Table 1 Analysis Conditions

[HPLC conditions] (Nexera™)	
Column	C18 ODS Column (50 mm × 2.1 mm I.D., 2.5 μm)
Mobile phases	A) 50 mmol/L HFIP and 10 mmol/L DIPEA B) Acetonitrile
Gradient program	B 5 % (0-0.5 min) – 15 % (0.5-3 min)
Flow rate	0.2 mL/min
Column temp.	60 °C
Injection volume	2 μL
[MS conditions] (LCMS-8060)	
Ionization	ESI (Negative mode)
Probe voltage	-4 kV
Mode	Full scan (m/z 500 - 2000) MRM (m/z 803.5 > 95.0)
CID gas	330 kPa
Nebulizing gas flow	3.0 L/min
Drying gas flow	8.0 L/min
Heating gas flow	12.0 L/min
DL temp.	300 °C
Heat block temp.	450 °C
Interface temp.	250 °C

*1 Triethylamine

*2 1,1,1,3,3,3-Hexafluoro-2-propanol

*3 N,N-diisopropylethylamine



Appearance of LCMS™-8060

■ Sample

Sequence: 5'-mG-mC*-mU*-mC*-dA-dG-dT-dC*-dT-dG-dC*-dT-dT-dC*-mG-mC*-mA-mC*-mC*-3'

(m) 2'-O-(2-methoxyethyl) nucleoside (2'-MOE)

(*) Indicates 5-C or 5-U methylation

(d) 2'-deoxynucleoside

Average mass: 6436.39

■ Calibration Curve

Fig. 1 shows a representative chromatogram acquired in the MRM mode, and Fig. 2 shows the calibration curve. The calibration curve was prepared for the range of 1 to 300 ng/mL. The coefficient of determination (R²) was 0.998.

Q 803.50>95.00 (-)




Fig. 1 MRM Chromatogram of Oligonucleotide Therapeutics




Fig. 2 Calibration Curve

Scan Mode Chromatogram and Mass Spectrum

Fig. 3 shows the mass chromatogram measured in the scan mode. In the mass chromatogram, hexavalent, heptavalent, and octavalent ions were selected.




Fig. 3 Mass Chromatogram of Oligonucleotide Therapeutics

Fig. 4 shows the mass spectrum. Pentavalent to octavalent ions were detected.




Fig. 4 Mass Spectrum of Oligonucleotide Therapeutics

Deconvolution by Multivalent Ion Analysis Software

Fig. 5 shows the results of a molecular weight calculation using the deconvolution function of the LabSolutions™ LCMS software. The target mass spectrum is displayed on LabSolutions LCMS, and multivalent ion analysis can be conducted simply by selecting the deconvolution menu.

As shown in the deconvolution results, the estimated molecular weight was confirmed to be 6436.37 (theoretical value: 6436.39). Thus, the molecular weight could be confirmed in a small error range.




Fig. 5 Results of Multivalent Ion Analysis

Conclusion

An example of an analysis of a 2'-MOE modified oligonucleotide using an LCMS-8060 triple quadrupole mass spectrometer was introduced. A calibration curve for the range of 1 to 300 ng/mL could be obtained, and the molecular weight could be confirmed in a small error range by deconvolution function from the scan data.

LCMS, Nexera and LabSolutions are trademarks of Shimadzu Corporation in Japan and/or other countries.



For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Shimadzu disclaims any proprietary interest in trademarks and trade names used in this publication other than its own. See <http://www.shimadzu.com/about/trademarks/index.html> for details.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.